Verve Therapeutics Management
Management criteria checks 2/4
Verve Therapeutics' CEO is Sek Kathiresan, appointed in Jul 2019, has a tenure of 5.5 years. total yearly compensation is $9.32M, comprised of 6.4% salary and 93.6% bonuses, including company stock and options. directly owns 0.8% of the company’s shares, worth $5.01M. The average tenure of the management team and the board of directors is 3.2 years and 3.7 years respectively.
Key information
Sek Kathiresan
Chief executive officer
US$9.3m
Total compensation
| CEO salary percentage | 6.4% |
| CEO tenure | 5.5yrs |
| CEO ownership | 0.8% |
| Management average tenure | 3.2yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Dec 08
Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio
Aug 30Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78
Aug 10We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
Jul 12Why Verve Therapeutics Deserves A Spot On Your Watchlist
Jun 13Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher
May 14The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Apr 03Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Feb 13Vectoring In On Verve Therapeutics
Jan 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Verve Therapeutics: Cathie Wood Adds To ARKK
Sep 20Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate
Aug 23Verve Therapeutics falls postmarket on $200M stock offering
Jul 20More CRISPR In Human Subjects
Jul 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Verve Therapeutics: Early-Stage Biotech With A Large Market
Apr 16Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans
Jan 31Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing
Aug 24Verve Therapeutics jumps 75% in its first day of trading
Jun 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$197m |
| Jun 30 2024 | n/a | n/a | -US$193m |
| Mar 31 2024 | n/a | n/a | -US$197m |
| Dec 31 2023 | US$9m | US$597k | -US$200m |
| Sep 30 2023 | n/a | n/a | -US$193m |
| Jun 30 2023 | n/a | n/a | -US$192m |
| Mar 31 2023 | n/a | n/a | -US$179m |
| Dec 31 2022 | US$8m | US$571k | -US$157m |
| Sep 30 2022 | n/a | n/a | -US$148m |
| Jun 30 2022 | n/a | n/a | -US$125m |
| Mar 31 2022 | n/a | n/a | -US$137m |
| Dec 31 2021 | US$6m | US$519k | -US$120m |
| Sep 30 2021 | n/a | n/a | -US$113m |
| Jun 30 2021 | n/a | n/a | -US$99m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | US$2m | US$480k | -US$46m |
Compensation vs Market: Sek's total compensation ($USD9.32M) is above average for companies of similar size in the US market ($USD3.22M).
Compensation vs Earnings: Sek's compensation has increased whilst the company is unprofitable.
CEO
Sek Kathiresan (51 yo)
5.5yrs
Tenure
US$9,319,782
Compensation
Dr. Sekar Kathiresan, M.D., also known as Sek, is Independent Director of Maze Therapeutics, Inc. He is Independent Director at Relay Therapeutics, Inc. since July 2022. He Co-Founderd at Maze Therapeutics...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5.5yrs | US$9.32m | 0.80% $ 5.0m | |
| CFO & Principal Accounting Officer | 3.2yrs | US$3.48m | 0.0063% $ 39.8k | |
| President | 6.4yrs | US$3.32m | 0.40% $ 2.5m | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | US$7.97k | no data | |
| Co-Founder | no data | no data | no data | |
| Co-Founder & Strategic Advisor | no data | no data | no data | |
| Chief Scientific Officer | less than a year | no data | 0.0021% $ 13.4k | |
| Chief Administrative Officer | 1.9yrs | no data | 0.010% $ 64.2k | |
| Vice President of Investor Relations & Corporate Communications | 3.2yrs | no data | no data | |
| Executive Director of Human Resources | 1.9yrs | no data | no data |
3.2yrs
Average Tenure
55yo
Average Age
Experienced Management: VERV's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5.5yrs | US$9.32m | 0.80% $ 5.0m | |
| Co-Founder & Scientific Advisory Board Member | 3.3yrs | US$7.97k | no data | |
| Co-Founder & Independent Chairman of the Board | 6.9yrs | US$451.88k | 0.51% $ 3.2m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.7yrs | US$521.07k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$412.38k | 0% $ 0 | |
| Independent Director | 2.4yrs | US$407.38k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Independent Director | 6.4yrs | US$410.88k | 0% $ 0 | |
| Independent Director | 2.6yrs | US$405.88k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.7yrs
Average Tenure
54.5yo
Average Age
Experienced Board: VERV's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 09:37 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Verve Therapeutics, Inc. is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Clarence Powell | BMO Capital Markets Equity Research |
| Whitney Ijem | Canaccord Genuity |